



**Andrew Hill**

**Kontakt**

Andrew Hill

## Publikationen (4)

Ciaffi L, Calmy A, Montecucco F, Hirschel B, Schmid P, Stoeckle M, Fehr J, Wandeler G, Hill A, Spycher Elbes R, Delhumeau C, Genné D, Cavassini M, Swiss HIV Cohort Study. Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study. *Eur J Clin Invest* 2015

Ananworanich J, Leduc D, Satchell C, Yerly S, Perrin L, Hill A, Perneger T, Phanuphak P, Furrer H, Cooper D, Ruxrungtham K, Hirschel B, Staccato Study Group, Bernasconi E, Vernazza P, Nüesch R, Gayet-Ageron A, Le Braz M, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawasdikul S, Sirivichayakul S, Cavassini M, Karrer U, Genné D, Swiss HIV Cohort Study. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. *Lancet* 2006; 368:459-65.

Tillmann H, Lundgren J, Dragsted U, Hill A, Vernazza P, Monforte A, Antunes F, Staszewski S, Fox Z, Kaiser T, MaxCmin1 Trial Group. Impact of coinfection with HIV-1 and GB virus C in patients receiving a ritonavir-boosted HAART regimen: a substudy to the MaxCmin1 trial. *Journal of acquired immune deficiency syndromes (1999)* 2005; 40:378-80.

Dragsted U, Lundgren J, Fox Z, Youle M, Vernazza P, Cassetti I, Hill A, Benetucci J, Bruun J, Clumeck N, Cahn P, Castagna A, Obel N, Duran A, Peters B, Pedersen C, Gerstoft J, MaxCmin1 Trial Group. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. *The Journal of infectious diseases* 2003; 188:635-42.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)